Imagion Biosystems (ASX:IBX) gets FDA green light for HER2 trial, recruitment starts Q3

IND 165081 puts MagSense in front of real patients across an 18-24 month readout

After nearly nine years on the ASX, Imagion Biosystems (ASX:IBX) has finally cleared the regulatory hurdle that turns a science story into a clinical one. The US FDA has issued a Study May Proceed Notice on the company’s Investigational New Drug application for the MagSense HER2 Imaging Agent, assigning IND number 165081 and allowing the Phase 1b/2 trial in HER2-positive breast cancer to begin.

For a clinical-stage diagnostics company, an IND clearance is the door opening. It means the FDA has reviewed the preclinical data, manufacturing controls, quality systems and trial protocol, and decided the science is safe enough to be tested in humans at the next level.

Patient recruitment is now targeted for the third quarter of 2026, with site contracting already underway. The principal investigator is Dr Eghtedari at City of Hope in Los Angeles, who also independently reviewed the earlier Phase 1 work. The trial itself is expected to run 18 to 24 months across three sequential parts, with interim readouts after Part A and Part B.

That sets up a steady drumbeat of catalysts for a stock that has spent years being judged on promises rather than data.

What the IND actually unlocks for MagSense

MagSense is a targeted MRI imaging agent. In plain English, it uses tiny iron oxide nanoparticles attached to antibodies that bind to cancer cells, making tumours show up far more sharply on an MRI scan than they would otherwise.

The Phase 1 study already showed that independent radiologists could see a clear visual difference between cancer-involved lymph nodes and clean ones. The Phase 1b/2 trial is about turning that visual signal into a measurable, dose-optimised diagnostic with statistical performance data.

The key point is that the trial design has three parts. Part A collects additional safety data on an initial cohort, Part B tests an optimised dose and imaging protocol, and Part C is the larger group that establishes diagnostic performance. Each stage produces a readout, which gives investors multiple chances to reassess the story before the final result.

Why HER2-positive breast cancer is the right target market

Roughly 450,000 women globally are diagnosed with HER2-positive breast cancer each year. It is the aggressive subtype, with higher recurrence and metastasis rates, which means accurate staging of lymph node spread directly changes treatment decisions.

Today, most nodal assessment is done with ultrasound, which is cheap and convenient but produces wildly variable sensitivity and specificity. MRI is more accurate but lacks molecular targeting. MagSense is designed to plug exactly into that gap, giving radiologists both the tissue detail of MRI and the molecular precision of a targeted agent, without ionising radiation.

If the Phase 1b/2 data holds up, Imagion’s commercial pitch writes itself” A non-radioactive, MRI-compatible agent that improves diagnostic certainty in an aggressive cancer subtype. Believe us, this is the kind of asset large imaging players would want to license rather than build.

The funding question that has not gone away

We think the most important number in this announcement is not in the announcement. An 18-to-24 month trial across three parts, with site activation, clinical contracting, manufacturing of trial material and data analysis, costs real money.

Imagion raised A$3.5 million at 1.5 cents per share to get to this point. Our concern is that this capital does not stretch all the way through a Phase 1b/2 readout, which means another raise during the trial is the likely base case. At current share price levels, any further dilution would be material.

The skeptical read is that today’s IND clearance was the milestone needed to support a stronger valuation in the next raise. The constructive read is that interim Part A safety data could land before that raise is required, giving the company a better window. Both can be true at the same time.

The Investors Takeaway for Imagion Biosystems

IBX has spent the last few years in a frustrating holding pattern, with the technology repeatedly described as promising while investors waited for the actual trial to start. That waiting period now has an end date. Recruitment in Q3 2026, Part A safety data after that, and Part B dosing data feeding into the larger Part C performance cohort.

We covered the lead-up to this moment in our previous note at stocksdownunder, and the setup has now firmed up considerably. The two things to watch from here are how quickly site activation translates into actual enrolment, and whether the company can fund through to a meaningful interim readout without a dilutive raise at the wrong price.

If both go right, IBX is one of the few ASX clinical-stage diagnostics names with a clear, dated catalyst path. If either slips, the story stays where it has been for years, which is interesting but unproven.

Imagion is a research client of Pitt Street Research.